Guest
Dr. Paul Richardson, Dana-Farber Cancer Institute, presents the preliminary results from the dose-expansion phase of the CC-92480-MM-001 trial studying Mezigdomide combined with Dexamethasone in relapsed/refractory multiple myeloma patients. Background: Mezigdomide (MEZI), a novel oral CELMoD® agent with enhanced tumoricidal and immune-stimulatory effects compared to immunomodulatory drugs (IMiDs®), induces maximal degradation of Ikaros and Aiolos, leading to increased apoptosis in myeloma cells. Preclinically, MEZI demonstrated potent synergy with DEX, proteasome inhibitors (PIs), and anti-CD38 monoclonal antibodies (mAbs). CC-92480-MM-001 (NCT03374085) is an ongoing phase 1/2 trial evaluating MEZI alone or in combination with DEX in pts with RRMM; in phase 1, the recommended phase 2 dose (RP2D) of MEZI in combination with DEX was selected at 1 mg once daily for 21/28 days (Richardson PG, et al. J Clin Oncol 2020;30[15 suppl]:8500). Here we report results from the dose-expansion cohort of MEZI DEX in pts with heavily pretreated RRMM. Conclusions: MEZI DEX had a manageable safety profile and demonstrated promising efficacy in pts with triple-class refractory RRMM, including pts with prior BCMA-targeted therapies, with an ORR of 40% and 50% respectively. These results support the development of MEZI in pts with MM. MEZI is currently being evaluated in combination with standard therapies in MM as part of a large, ongoing phase 1/2 trial (NCT03989414) and phase 3 trials in combination with PIs are planned. Authors: Paul G. Richardson, MD, Suzanne Trudel, Hang Quach, Rakesh Popat, Sagar Lonial, MD, Robert Z. Orlowski, MD, PhD, Kihyun Kim, MD, María-Victoria Mateos, MD, PhD, Charlotte Pawlyn, PhD, Karthik Ramasamy, Joaquín Martinez-Lopez, MD, PhD, Alessia Spirli*, Ignacio Casas-Avilés, MD, Jing Gong, PhD, Michael Amatangelo, PhD, Jessica Katz, MD PhD, Paulo Maciag, MD PhD, Teresa Peluso and Nizar J. Bahlis, MD ASH Abstract# 568: _______________ Improving Lives | Finding the Cure Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy. Subscribe to our channel: Visit our website at: Find us online: Facebook: @myeloma | Twitter: @IMFMyeloma | Instagram: @imfmyeloma | LinkedIn: Support the IMF | Donate Now! Category Nonprofits & Activism License Standard YouTube License In most cases, captions are autogenerated by YouTube.
